News

The opinion will now be referred to the European Commission for final regulatory decision on donanemab  INDIANAPOLIS, July 25 ...
Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...
Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a ...
Basel: Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
Pharmaceutical Technology on MSN2d
CHMP rejects Elevidys in latest setback for Sarepta
Sarepta has suffered another regulatory setback after the European Medicines Agency’s (EMA’s) Committee for Medicinal ...
Gilead Sciences (NASDAQ:GILD) announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for ...
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 January 2014 By Emily Wasserman Jan 24, 2014 7:35am Pharma ...
LONDON, Oct. 23, 2008-On 23 October 2008 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion** to recommend the variation to the terms of the marketing ...
STOCKHOLM, Feb. 28, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP) of the ...
Committee for Medicinal Products for Human Use Summary of Positive Opinion for Optaflu LONDON, April 26, 2007-On 26 April 2007 the Committee for Medicinal Products for Human Use (CHMP) adopted a ...
DGAP-News: Moderna, Inc. / Key word(s): MiscellaneousEMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of Moderna's ...
The Committee adopted positive opinions recommending the granting of marketing authorisations for the following new medicines: Eliquis (apixaban), from Bristol-Myers Squibb/Pfizer EEIG, intended ...